Page last updated: 2024-12-08

schizandrer a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

schizandrer A: from Fructus Schizandrae chinensis (Schisandraceae); structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID163338
MeSH IDM0106474

Synonyms (14)

Synonym
schizandrer a
benzo(3,4)cycloocta(1,2-f)(1,3)benzodioxole-5,6-diol, 5,6,7,8-tetrahydro-6,7-dimethyl-1,2,3,13-tetramethoxy-, 5-benzoate, stereoisomer
benzo(3,4)cycloocta(1,2-f)(1,3)benzodioxole-5,6-diol, 5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethyl-, 5-benzoate, stereoisomer
82042-38-4
benzo[3,4]cycloocta[1,2-f][1,3]benzodioxole-5,6-diol,5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethyl-, 5-benzoate, (5r,6r,7s)-
benzoylgomisin p
6-hydroxy-1,2,3,13-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-11h-benzo[3',4']cycloocta[1',2':4,5]benzo[1,2-d][1,3]dioxol-5-yl benzoate
DTXSID901002412
[(8r,9r,10s)-9-hydroxy-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-8-yl] benzoate
E88963
129445-43-8
CS-0140365
HY-N2988A
FS-7267

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" In this work, plasma pharmacokinetic characteristics of lignans components after oral administration SMS were investigated using UPLC-Q-TOF/MS method."( Pharmacokinetic study of schisandrin, schisandrol B, schisantherin A, deoxyschisandrin, and schisandrin B in rat plasma after oral administration of Shengmaisan formula by UPLC-MS.
Han, Y; Sun, H; Wang, X; Wei, W; Wu, F; Zhang, A, 2013
)
0.39
" This paper was designed to study on the plasma pharmacokinetic for its absorption process, and to compare the pharmacokinetics of its active ingredients in normal and insomnic rats orally administrated with the prescription."( Development of a UFLC-MS/MS method for simultaneous determination of six lignans of Schisandra chinensis (Turcz.) Baill. in rat plasma and its application to a comparative pharmacokinetic study in normal and insomnic rats.
Bi, K; Chen, X; Fan, R; Geng, L; He, B; Jia, Y; Li, Q; Su, D; Wei, B; Zhao, L, 2013
)
0.39
" After oral administration of FZHY at a dose of 15g/kg, the pharmacokinetic behaviors of schizandrin A (SIA), schizandrin B (SIB), schizandrin C (SIC), schisandrol A (SOA), Schisandrol B (SOB) and schisantherin A (STA) have been significantly changed in hepatic fibrosis rats compared with the normal rats, and their AUC(0-t) values were increased by 235."( Comparative pharmacokinetics and tissue distribution profiles of lignan components in normal and hepatic fibrosis rats after oral administration of Fuzheng Huayu recipe.
Liu, CH; Liu, S; Tao, YY; Yang, T; Zheng, TH, 2015
)
0.42
" We aimed to predict the contribution of schisantherin A and schisandrin A to drug-drug interaction (DDI) between Wuzhi capsule and tacrolimus using physiologically-based pharmacokinetic (PBPK) modelling."( Prediction of Drug-Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically-Based Pharmacokinetic Modelling.
Bu, F; Cai, W; Jiao, Z; Li, L; Lin, HS; Ma, G; Shin, JG; Xiang, X; Zhang, H; Zhuang, X, 2018
)
0.48
" The essential adjusted physicochemical data and pharmacokinetic parameters of SIA, STA, and CsA were collected."( The Pharmacokinetic Prediction of Cyclosporin A after Coadministration with Wuzhi Capsule.
Chen, L; Fan, J; Li, M; Lu, X; Zhu, L, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
" After dynamic catalytic transformation by 201×7 resin combined with purification of HPD5000 resin, the yield and the purity of free biphenyl cyclooctene lignans in the product were 132."( Preparation of high purity biphenyl cyclooctene lignans from Schisandra extract by ion exchange resin catalytic transformation combined with macroporous resin separation.
Liu, TT; Ma, CH; Yang, FJ; Yang, L; Zhang, L; Zhang, ZH; Zhao, CJ; Zu, YG, 2011
)
0.37
" We aimed to predict the contribution of schisantherin A and schisandrin A to drug-drug interaction (DDI) between Wuzhi capsule and tacrolimus using physiologically-based pharmacokinetic (PBPK) modelling."( Prediction of Drug-Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically-Based Pharmacokinetic Modelling.
Bu, F; Cai, W; Jiao, Z; Li, L; Lin, HS; Ma, G; Shin, JG; Xiang, X; Zhang, H; Zhuang, X, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" Six lignans pretreatment before APAP dosing could prevent the depletions of total liver glutathione (GSH) and mitochondrial GSH caused by APAP."( Hepato-protective effects of six schisandra lignans on acetaminophen-induced liver injury are partially associated with the inhibition of CYP-mediated bioactivation.
Bi, H; Chen, P; Fan, X; Huang, M; Jiang, Y; Tan, H; Wang, Y; Zeng, H, 2015
)
0.42
" At the dosage of 20 μmol•L⁻¹, schisantherin A attenuated the migration and tube formation of SK-HEP-1 cells induced by VEGF, and also inhibition the formation of rat aortic rings and intersegmental vessel changes of transgenic zebrafish, and significantly reduce the number of vessels in zebrafish."( [Effect of schisantherin A inhibit liver sinusoid endothelial cell function and action against liver fibrosis relating to angiogenesis].
Liu, CH; Lv, J; Tao, YY; Zhao, ZM; Zhu, CW, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (64)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (4.69)18.7374
1990's1 (1.56)18.2507
2000's6 (9.38)29.6817
2010's44 (68.75)24.3611
2020's10 (15.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.54 (24.57)
Research Supply Index4.19 (2.92)
Research Growth Index5.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other65 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]